News & Events CTI Regulatory Director to Present at American Society of Gene and Cell Therapy and Serve on Government Relations Committee

CTI Regulatory Director to Present at American Society of Gene and Cell Therapy and Serve on Government Relations Committee

May 16, 2018

FOR IMMEDIATE RELEASE [Covington, KY ~ May 16, 2018] 

CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization will present as part of The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 16-19, 2018 in Chicago, IL. Angela N. Johnson, MSE, Associate Director, Regulatory and Scientific Affairs will present her abstract entitled, "The Gap between Clinician-Led Cell Therapy Evidence and Marketed Products: a Quasi-Experimental Comparative Pilot Study of Young Venture Clinical Development," on Friday May 18, 5:45p-7:45p. 

Additionally, in recognition of her leadership in the field, Johnson has been asked to serve as a member of the Government Relations Committee for the American Society of Gene & Cell Therapy. This committee is charged with developing and maintaining productive ASGCT relationships with government entities, including NIH, FDA and legislative bodies.  The intent is to educate these entities regarding the current status and future potential of gene and cell therapies, to convey the need for enhanced funding, and to work with the FDA towards an optimized regulatory environment for gene and cell therapies.


"We are thrilled that Angela has not only been invited to present at ASGCT, but also serve on such a prestigious committee," according to Lynn Fallon, President of CTI. "Angela's background in regulatory and medical writing, as well as her experience in gene and cell therapy research is a huge asset to both our sponsors and our staff."

The American Society of Gene and Cell Therapy Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. As a leading American conference focusing solely on gene and cell therapy, ASGCT's annual meeting brings together over 2,500 professionals including scientists, physicians, and patient advocates.

Johnson is the author of the recent May 2018 Editor’s Choice article “Gene Therapy Harmonization Milestones and Challenges” published in Regulatory Focus, the flagship journal of the Regulatory Affairs Professionals Society (RAPS). The article focuses on historical and forward-looking international efforts between regulators, patient advocacy groups, and large and small industry organizations to harmonize and advance development of gene therapy products.

Johnson is also currently a doctoral researcher at Texas Tech University, Department of English, School of Technical Communication, Science & Healthcare Concentration, where she works with Associate Professor Dr. Rich Rice examining the international and intercultural effects of biopharmaceutical product development and telehealth in India, China, South Africa, and other global regions. Prior to joining CTI, Johnson's previous experience includes leadership roles in the clinical research division of GE Healthcare’s Technology and Medical Innovation Organization and previous medical regulatory writing roles in both domestic and global contract research organizations.

Johnson and her co-authors were recently awarded the prestigious Lucien Levy Best Original Research Article of 2017 Award from the American Journal of Neuroradiology for her contributions to the manuscript "Synthetic MRI for Clinical Neuroimaging: Results of the Magnetic Resonance Image Compilation (MAGiC) Prospective, Multicenter, Multireader Trial".

Subscribe to our mailing list

* indicates required